- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05333874
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage Breast Cancer
Primary Objective:
1) To examine the impact of Circulating tumor DNA (ctDNA) (expressed as mean tumor molecules per ml) on treatment decision making in patients with early stage breast cancer after neoadjuvant therapy and surgery
Secondary Objectives:
- Understand ctNDA kinetics in the neoadjuvant and adjuvant setting
- To identify any associations between clinical staging and measurable ctDNA
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To determine whether early detection of Circulating tumor DNA (ctDNA) after neoadjuvant systemic therapy help tailor adjuvant therapy and reduce risk of relapse in patients who are at increased risk of recurrence. Studies have shown the presence of ctDNA is associated with increased risk of relapse, it is unclear how adjuvant therapy and its effect of ctDNA impacts the risk of relapse. There is very limited data on the role of ctDNA monitoring and response to neoadjuvant/adjuvant systemic therapy in patients with human epidermal growth factor receptor 2 (HER2 ) positive breast cancer.
Natera, Inc. (NASDAQ: NTRA) has developed a minimal residual disease (MRD) assay that sequences tumor tissue to identify a unique signature of tumor mutations, then customizes a personalized PCR assay for each participant, targeting the top 16 clonal mutations found in the tumor (Signatera™). Signatera is intended to detect and quantify how much cancer is left in the body, to improve prognosis and help optimize treatment decisions, based on the tissue-informed testing of mutations.
If the ctDNA blood test is positive, change in treatment can be made after discussion with the participant and treating provider. If the decision is for observation (Observation defined for TNBC: No adjuvant chemotherapy. Participants may complete checkpoint inhibitor from neoadjuvant setting. HER2 positive breast cancer: complete 12 months of anti-HER2 therapy, which was initiated in neoadjuvant setting), participants in the observation arm, will be monitored for ct-DNA re-emergence and systemic therapy can be added at the time of ctDNA re-emergence. If the decision is made to institute systemic therapy based on the ctDNA detection, participants will be monitored with ctDNA at 60days, 3 months, 6 months, 9 months, 12 months, 18months and 24months from surgery. If ctDNA is negative, there will be no change in therapy and participants can continue on observation arm (Observation defined for TNBC: No adjuvant chemotherapy. Participants may complete checkpoint inhibitor from neoadjuvant setting. HER2 positive breast cancer: complete 12 months of anti-HER2 therapy, which was initiated in neoadjuvant setting). Participants in the observation arm will be monitored for ct-DNA re-emergence and systemic therapy can be added at the time of ctDNA re-emergence.
The treating oncologist will complete a questionnaire to determine how ctDNA impacts treatment decisions in the adjuvant setting once the results from the fourteen day ctDNA is available and at the time of ctDNA re-emergence. Participants will complete participant questionnaire at 3 months, 6months,12months and 24 months post-operatively. Participants will be followed up for five years.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
New Jersey
-
Elizabeth, New Jersey, United States, 07202
- Trinitas Hospital and Comprehensive Cancer Center
-
Hamilton, New Jersey, United States, 08690
- RWJBarnabas Health - Robert Wood Johnson University Hospital
-
Jersey City, New Jersey, United States, 07302
- Jersey City Medical Center
-
Lakewood, New Jersey, United States, 08701
- Monmouth Medical Center - Southern Campus
-
Livingston, New Jersey, United States, 07052
- Cooperman Barnabas Medical Center
-
Long Branch, New Jersey, United States, 07740
- Monmouth Medical Center
-
New Brunswick, New Jersey, United States, 08903
- Rutgers Cancer Institute of New Jersey
-
New Brunswick, New Jersey, United States, 08901
- Robert Wood Johnson University Hospital
-
Newark, New Jersey, United States, 07112
- Newark Beth Israel Medical Center
-
Somerville, New Jersey, United States, 08876
- Robert Wood Johnson Barnabas Hospital -Somerset
-
Somerville, New Jersey, United States, 08876
- Steeplechase Cancer Center
-
West Long Branch, New Jersey, United States, 07746
- Monmouth Medical Center Vantage Point Infusion Cente
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants with a diagnosis of clinical Stage II-III triple negative and/or HER2 positive breast cancer
- Age ≥ 18 years
- Estimated life expectancy of at least twelve months
- Participant must be eligible for neoadjuvant systemic therapy per treating physician
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Able to provide signed and dated informed consent form
- Must have ctDNA at the time of screening to be eligible for the study
- Participants enrolled on other systemic therapy trials may be eligible to participate in the study after discussion with principal investigator
- Be willing to present for medical exams and blood draws as scheduled per protocol
Exclusion Criteria:
- Evidence of metastatic breast cancer
- Any other concurrent malignancy
- Prior malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) unless a complete remission was achieved at least one year prior to study entry
- Participant is pregnant
- Serious concomitant systemic disorder that would compromise the safety of the participant or compromise the participant's ability to complete the study, at the discretion of the investigator
- Bone marrow transplant or other organ transplant recipient
- History of psychiatric illness or social situations that would limit compliance with study requirements
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Neoadjuvant chemotherapy
If Circulating tumor DNA (ctDNA) blood test is positive, change in treatment can be made. Participants will be monitored with ctDNA at 60days, 3 months, 6 months, 9 months, 12 months, 18months and 24months from surgery. The participant's core biopsy specimens will be sent to NateraTM to sequence the primary tumor. The baseline blood work for ctDNA will be collected prior to the initiation of systemic therapy. Subsequently, ctDNA will be collected prior to each cycle of neoadjuvant chemotherapy. Participants will undergo surgery and ctDNA needs to be collected fourteen days post-surgery The treating oncologist will complete a questionnaire to determine how ctDNA impacts treatment decisions in the adjuvant setting once the results from the fourteen day ctDNA is available and at the time of ctDNA re-emergence. Participants will complete participant questionnaire at 3 months, 6months, 12months and 24 months post-operatively. |
SignateraTM is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer.
The Signatera methodology is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual's tumor tissue.
This maximizes accuracy for detecting the presence or absence of disease in a blood sample, even at levels down to a single tumor molecule in a tube of blood.
Signatera is intended to detect and quantify how much cancer is left in the body, to improve prognosis and help optimize treatment decisions, based on the tissue-informed testing of mutations.
Other Names:
|
Other: Observational
Observation for triple negative breast cancer (TNBC): No adjuvant chemotherapy.
Patients may complete checkpoint inhibitor from neoadjuvant setting.
human epidermal growth factor receptor 2 (HER2) positive breast cancer: complete twelve months of anti-HER2 therapy, which was initiated in neoadjuvant setting), participants in the observation arm, will be monitored for Circulating tumor DNA (ct-DNA) re-emergence and systemic therapy can be added at the time of ctDNA re-emergence.
|
In participants, undetectable ctDNA at fourteen days will be in the observation arm (observation defined as TNBC: No adjuvant chemotherapy.
Participants may complete checkpoint inhibitor from neoadjuvant setting; HER2 positive BC: Completed one year of anti-HER2 therapy from the neoadjuvant setting).
No investigational drugs will be used.
Samples of ctDNA will be collected at time points described in the study arm.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detectable Circulating tumor DNA ctDNA
Time Frame: Five Years
|
Participants with detectable ctDNA fourteen days post-operatively will have the option to change adjuvant therapy after discussion with primary provider.
SignateraTM is intended to detect and quantify how much cancer is left in the body, to improve prognosis and help optimize treatment decisions, based on the tissue-informed testing of mutations.
|
Five Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Levels of Detectable Circulating tumor DNA ctDNA
Time Frame: Five Years
|
Participants on observation or change in adjuvant therapy will continue to be monitored with ctDNA at 60 days, 3 months, 6 months, 9 months, 12 months, 18months and 24months from surgery.
|
Five Years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mridula George, MD, Rutgers Cancer Institute of New Jersey
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 042110
- Pro2022000044 (Other Identifier: Rutgers, The State University of New Jersey)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer, Early-Onset
-
Helsinki University Central HospitalUniversity of Helsinki; Noona HealthcareCompletedBreast Cancer, Early-Onset
-
MedSIRRecruitingBreast Cancer | Breast Cancer, Early-OnsetSpain, France
-
Intuitive SurgicalRecruitingBreast Cancer | Breast Cancer Female | Breast | Breast Disease | Breast Cancer, Early-OnsetUnited States
-
Nij Smellinghe HosptialCompletedLymphedema | Breast Cancer Stage II | Early Disease OnsetNetherlands
-
Cairo UniversityNot yet recruitingEarly Disease Onset
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Weill Medical College of Cornell UniversityJohns Hopkins University; Mayo Clinic; National Heart, Lung, and Blood Institute... and other collaboratorsRecruiting
-
Fudan UniversityCompletedEarly-onset Colorectal Cancer | Late-onset Colorectal Cancer
-
Nantes University HospitalUniversity Hospital, Angers; University Hospital, Bordeaux; Poitiers University... and other collaboratorsCompletedEarly-onset Neonatal InfectionFrance
-
AstraZenecaRecruitingBreast Cancer, Early Breast CancerUnited States, Canada, United Kingdom, China, Argentina, Australia, Hungary, Netherlands, Korea, Republic of, France, Germany, Italy, Belgium, Bulgaria, India, Mexico, Spain, Vietnam, Colombia, Japan, Peru, Brazil, Malaysia, Taiwan, Tha... and more
Clinical Trials on Neoadjuvant chemotherapy administered before surgical extraction of a tumor
-
Rigshospitalet, DenmarkRecruiting
-
University of Texas Southwestern Medical CenterRecruitingBrain MassUnited States
-
Riyadh Colleges of Dentistry and PharmacyNot yet recruitingAlveolar OsteitisSaudi Arabia
-
Region SkaneRecruitingMetastatic Colorectal Cancer | Lung Metastases | Chemotherapy Effect | Peritoneal Metastases | Liver Metastasis Colon CancerSweden
-
University Hospital, AngersRecruitingDevelopment Delay | Cancer Childhood | Predisposition, GeneticFrance, Réunion
-
Roswell Park Cancer InstituteCompleted
-
Universitätsklinikum Hamburg-EppendorfCharite University, Berlin, Germany; University Hospital, Essen; Westpfalz-Clinical...Active, not recruiting
-
Medical University of ViennaUnknownColorectal Cancer | Peritoneal MetastasisAustria
-
Poznan University of Medical SciencesMagForce USARecruiting
-
Cari Health Inc.Samplimy Medical ABRecruitingPain, Chronic | Metabolism Medication Toxicity | Methadone Toxicity | Methadone Overdose | Drug Metabolism, Poor, CYP2D6-RelatedUnited States